Artiva Biotherapeutics, Inc. reported that its stockholders approved an amendment to the company's 2024 Equity Incentive Plan at the 2026 Annual Meeting of Stockholders held on September 8, 2026. The amendment, which was previously approved by the Board of Directors on July 15, 2026, subject to stockholder ratification, increases the number of shares of common stock authorized for issuance under the plan.
Specifically, the amendment authorizes an increase of 5,097,095 shares of common stock. Additionally, the amendment modifies the calculation of the plan's annual automatic share reserve increase to include shares of common stock issuable upon the exercise of any pre-funded warrants. The full details of the plan are available in the company's definitive proxy statement filed with the SEC on August 3, 2026.
The final voting results for the proposal were as follows: 32,527,133 votes in favor, 6,816,989 votes against, and 22,759 abstentions. Broker non-votes totaled 4,640,922.
At the Annual Meeting, the company also elected two Class II directors to serve three-year terms through the 2029 annual meeting. Brian Daniels, M.D., received 33,591,967 votes for and 5,774,914 votes withheld. Laura Stoppel, Ph.D., received 33,862,513 votes for and 5,504,368 votes withheld. The meeting also included the ratification of KPMG LLP as the principal independent registered public accounting firm for the fiscal year ending December 31, 2026, which received 44,000,762 votes for and 4,325 votes against.
